Alto Neuroscience ANRO Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$26.24M-73.0% | -$16.18M-6.5% | -$14.18M+15.5% | -$17.71M-10.5% | -$15.17M-13.1% | ||
| $184K+7.6% | $157K-7.6% | $200K0.0% | $100K0.0% | $171K+76.3% | ||
| $2.82M+43.5% | $1.95M+24.3% | $2.19M+9.6% | $2.01M+6.2% | $1.97M-9.7% | ||
| -$9K+78.0% | $0+100% | -$114K-2,750% | -$1K+94.4% | -$41K— | ||
| $1.49M+660% | —— | $461K+12.7% | $323K— | -$266K-124% | ||
| -$1.75M+35.1% | —— | —— | —— | -$2.7M-765% | ||
| $4.13M+144% | -$656K— | —— | —— | $1.69M-5.0% | ||
| $200K+5.3% | $197K-6.6% | $195K— | $192K+256% | $190K+164% | ||
| $0+100% | $0— | $0— | $0— | -$681K— | ||
| -$27.09M-63.6% | -$11.52M+11.6% | -$9.92M+15.4% | -$13.78M-17.8% | -$16.56M-50.7% | ||
| $556K+2,217% | —— | —— | —— | $24K-89.3% | ||
| -$556K-2,217% | —— | —— | —— | -$24K+89.3% | ||
| $0-100% | —— | —— | —— | $10.21M— | ||
| $6K-97.0% | $352K+618% | $153K+128% | $0-100% | $198K+1,880% | ||
| $190K— | —— | —— | —— | —— | ||
| $0-100% | —— | —— | —— | $127K— | ||
| $114.94M+1,159% | $50.19M+102,318% | $153K-88.4% | $613K— | $9.13M-93.2% | ||
| -$16K+27.3% | -$1K— | -$4K+42.9% | -$3K+40.0% | -$22K-340% | ||
| $87.28M+1,268% | $38.67M— | -$9.77M— | -$13.17M— | -$7.48M-106% | ||
| $342K+10.0% | $425K+71.4% | $465K+84.5% | $459K+82.9% | $311K+25.4% | ||
| $184K+7.6% | $157K-7.6% | $200K0.0% | $133K— | $171K— | ||
| $116K+183% | $91K+1,417% | $112K+133% | $83K— | $41K— | ||
| -$1.75M+35.1% | —— | —— | —— | -$2.7M-765% | ||
| $4.13M+144% | -$656K— | —— | —— | $1.69M-5.0% | ||
| $206K+14.4% | $175K+78.6% | $192K+93.9% | $182K+85.7% | $180K+83.7% | ||
| $200K+5.3% | $197K-6.6% | $195K— | $192K+256% | $190K+164% | ||
| $4.88M— | —— | —— | —— | $0— | ||
| $0-100% | —— | —— | —— | $127K— | ||
| $0-100% | —— | —— | $137K— | $419K— | ||
| $120M— | —— | —— | —— | $0— | ||
| $941K— | $3.73M+11,763% | —— | —— | $0-100% | ||
| $0-100% | —— | —— | —— | $19.69M— | ||
| $0-100% | —— | —— | —— | $524K— | ||
| $233K— | —— | —— | —— | $0— | ||
| $0-100% | —— | —— | —— | $138K+6,800% | ||
| -$27.65M-66.7% | -$11.52M+14.9% | -$9.92M+22.1% | -$13.78M-14.5% | -$16.58M-47.9% | ||
| -$27.65M-66.7% | -$11.52M+14.9% | -$9.92M+22.1% | -$13.78M-14.5% | -$16.58M-47.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Alto Neuroscience generate?
- Alto Neuroscience (ANRO) generated -$62.3M in operating cash flow over the trailing twelve months.
- What is Alto Neuroscience's free cash flow?
- After $2.1M of capital expenditures, Alto Neuroscience's free cash flow was -$62.9M over the trailing twelve months, down 14.6% year over year.
- Where does Alto Neuroscience's cash flow data come from?
- Every line is extracted from Alto Neuroscience's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.